Evidence map›Paper›PMID 25928322›Full record

ArticleMolecular cancer2015

miR-21 and miR-145 cooperation in regulation of colon cancer stem cells.

Yingjie Yu, Pratima Nangia-Makker, Lulu Farhana, Sindhu G Rajendra, Edi Levi, Adhip P N Majumdar

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Article
  3. miR-145 restoration overcomes oxaliplatin resistance via ABCC1 in colorectal cancer.Journal of the Egyptian National Cancer Institute · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yingjie YuDepartment of Veterans Affairs Medical Center, 4646 John R, Detroit, MI, 48201, USA. aa5142@wayne.edu.
Pratima Nangia-MakkerDepartment of Veterans Affairs Medical Center, 4646 John R, Detroit, MI, 48201, USA. makkerp@karmanos.org.
Lulu FarhanaDepartment of Veterans Affairs Medical Center, 4646 John R, Detroit, MI, 48201, USA. lfarhana@med.wayne.edu.
Sindhu G RajendraDepartment of Veterans Affairs Medical Center, 4646 John R, Detroit, MI, 48201, USA. sindhu25raj@gmail.com.
Edi LeviDepartment of Veterans Affairs Medical Center, 4646 John R, Detroit, MI, 48201, USA. Edi.Levi@va.gov.
Adhip P N MajumdarDepartment of Veterans Affairs Medical Center, 4646 John R, Detroit, MI, 48201, USA. a.majumdar@wayne.edu.
Wayne State University · USJohn D. Dingell VA Medical Center · USVeterans Health Administration · US

Funding

The Aging Gut:Regulation of Cell ProliferationR01AG014343 · NIA · WAYNE STATE UNIVERSITY · PI MAJUMDAR, ADHIP P. N. · 1997 to 2011
$2.8M
Differentiation and Elimination of Chemo-surviving Colon TumorsI01BX001927 · VA · JOHN D DINGELL VA MEDICAL CENTER · PI MAJUMDAR, ADHIP P. N. · 2013 to 2016
–
BLRD VA I01 BX001927NIA NIH HHS AG014343NIA NIH HHS R01 AG014343
6 · The paper itself

Abstract

backgroundAcquired drug resistance is one of the major reasons for failing cancer therapies. Although the reasons are not fully understood, they may be related to the presence of cancer stem cells (CSCs). We have reported that chemo-resistant (CR) colon cancer cells, highly enriched in CSCs, exhibit a marked up-regulation of miR-21 and that down-regulation of this miR renders the CR cells more susceptible to therapeutic regimens. However, the underlying molecular mechanism is poorly understood. The aim of this investigation is to unravel this mechanism.

methodsThe levels of miR-145 and miR-21 were manipulated by transfection of mature, antago-miRs or pCMV/miR-145 expression plasmid. Quantitative RT-PCR or/and Western blots were performed to examine the expression of CD44, β-catenin, Sox-2, PDCD4, CK-20 and k-Ras. Colonosphere formation and SCID mice xenograft studies were performed to evaluate the tumorigenic properties of CSC-enriched colon CR cells.

resultsWe investigated the role that microRNAs (miRs), specifically miR-21 and miR-145 play in regulating colon CSCs. We found the expression of miR-21 to be greatly increased and miR-145 decreased in CR colon cancer cells that are highly enriched in CSC, indicating a role for these miRNAs in regulating CSCs. In support of this, we found that whereas forced expression of miR-145 in colon cancer cells greatly inhibits CSCs and tumor growth, up-regulation of miR-21 causes an opposite phenomenon. In addition, administration of mature miR-145 or antagomir-21 (anti-sense miR-21) greatly suppresses the growth of colon cancer cell xenografts in SCID mice. This was associated with decreased expression of CD44, β-catenin, Sox-2 and induction of CK-20 indicating that administration of miR-145 or antagomir-21 decreases CSC proliferation and induces differentiation. In vitro studies further demonstrate that miR-21 negatively regulates miR-145 and vice versa. k-Ras appears to play critical role in regulation of this process, as evidenced by the fact that the absence of k-Ras in CR colon cancer cells increases miR-145 expression, suppresses miR-21, and interrupts the negative cooperation between miR-21 and miR-145.

conclusionsOur current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance.

Indexed as

Drug Resistance, NeoplasmAnimalsBiomarkers, TumorCarcinogenesisCell DifferentiationCell ProliferationColonic NeoplasmsDown-RegulationFeedback, PhysiologicalHCT116 CellsHT29 CellsHumansMice, SCIDMicroRNAsNeoplastic Stem CellsSpheroids, CellularBiomarkers, TumorMicroRNAsMIRN145 microRNA, humanMIRN21 microRNA, human

Identifiers

PMID25928322
PMCPMC4415383
OpenAlexW2063756587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.